December 19, 2016
Veloxis increases capital by 1,5M new shares
Danish pharmaceutical company Veloxis Pharmaceuticals A/S, has increased its capital by 1,500,000 new shares. The company said on Monday that…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
December 19, 2016
Chinese AceCGT bags distribution deal with Belgian MDxHealth for prostate cancer assay in Hong Kong and Macao
MDxHealth has signed a distribution agreement with AceCGT Life Science Limited for their SelectMDx for Prostate Cancer assay in Hong Kong…
December 16, 2016
Novartis’s epilepsy drug gets CHMP’s positive opinion
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for…
December 16, 2016
ABIVAX welcomes Didier Blondel as CFO
ABIVAX has appointed Didier Blondel as Chief Financial Officer, effective January 2nd, 2017.
December 16, 2016
FDA OK’s Cerenis’s CER-209 clinical trial for liver disease treatment
U.S. Food and Drug Administration (FDA) has given green light to Cerenis Therapeutics to proceed with CER-209 clinical trial.
December 16, 2016
Novartis buys Ziarco Group
Novartis has entered into a definitive agreement to buy a privately held company Ziarco Group Limited, focused on producing dermatology…
December 16, 2016
RAC Approves Cellectis’s UCART123 Phase 1 study protocols in AML and BPDCN
Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), has announced the National Institute…
December 16, 2016
MDxHealth Receives ISO 13485:2016 Certification for Dutch Laboratory
MDxHealth’s laboratory in Nijmegen, The Netherlands has received ISO 13485:2016 certification for the design, development, manufacture and distribution of in…
December 16, 2016
Allergan’s subsidiaries Forest to pay $38M for bad marketing practices
Allergan’s indirect subsidiaries Forest Laboratories, LLS and Forest Pharmaceuticals, Inc. are about to pay $38 million for bad sales and…
December 16, 2016
Valneva closes private placement in connection with EUR15.2m investment by MVM
French vaccines developer Valneva has closed the share issuance in connection with MVM Life Science Partners LLP`s investment in the…